The first problem is that far from being preprogrammed with a series of hardwired mental modules, as the E.P. types assert, our brains are fluid and plastic. We’re learning that evolution can be a more rapid process than we thought. It doesn’t take hundreds of thousands of years to produce genetic alterations.

    Part of the enjoyment of doing research is that ideas pop into your head all the time. Everyone has ideas, but the hard part is to choose which should be subjected to critical tests that have the primary aim of proving them wrong. That’s the most efficient way to discard bad ideas, because most of them in fact don’t work. Only after an idea survives the crucible of initial testing can it be taken more seriously and tested further. Then, if it still survives, you can publish.

The first two articles of this series have covered a brief overview of evolutionary psychology and the difficulty in defining and measuring intelligence. In the first article, I covered that we can measure what people prefer and value, but we don’t know the "why" behind those preferences and values.

An evolutionary psychologist from the London School of Economics, Satoshi Kanazawa, wrote a paper on the origin of individual values and preferences that suggests values are tied to IQ, and you can theoretically predict the values of a nation based on its average intelligence.

AMSTERDAM, The Netherlands, June 26 /PRNewswire/ -- The U.S. Department of Energy's Pacific Northwest National Laboratory has signed an agreement with Avantium to enable the sale and delivery of an Avantium Flowrence(TM) parallel fixed bed reactor system. The Flowrence(TM) will allow PNNL to accelerate its catalyst research for infrastructure compatible biofuels and bioproducts.

CASTRES, France, June 26 /PRNewswire/ -- Laboratoires Pierre Fabre announce today that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant marketing authorisation for JAVLOR(R) as monotherapy in metastatic treatment of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen).

CHMP has issued a positive opinion based on two phase II study results and on the only phase III randomized study ever conducted in the indication of metastatic treatment of bladder cancer after failure of a prior platinum-containing regimen.

COPENHAGEN, June 26 /PRNewswire/ --

- Agreement Delivers Greater Global Connectivity to Nordic Business and Enhances ATT's Local Reach in key Growth Region

ATT* and TDC today announced an agreement to jointly develop and deploy global service bundles and networking solutions for multinational companies, either headquartered or doing business in the Nordics, a region considered to be among the most technologically advanced and competitive in the world.

HATFIELD, England, June 26 /PRNewswire/ --

- Leading Research-Based Pharmaceutical Company Creates New Manufacturing and Research Jobs in UK

Eisai, one of the world's leading pharmaceutical companies, today officially opened its new 'European Knowledge Centre' (the EKC) in Hatfield, Hertfordshire.

OSLO, Norway, June 26 /PRNewswire/ -- Clavis Pharma ASA (OSE: CLAVIS) today announced that the Company has raised NOK 129 million (equivalent to USD 20 million) in gross proceeds through a private placement of 10,750,000 new shares, each with a par value of NOK 1.00 at a price of NOK 12.00 per share (the Private Placement).

CANNES, France, June 26 /PRNewswire/ --

4th annual global student competition demonstrates digital

concepts reaching the real world

AKQA presented the winning entries in its fourth annual Future Lions Competition at the Cannes Lions Festival held today in Cannes, France. The global creative competition featured work from more than 700 teams around the world. Students from five winning teams were introduced to top shops attending the Cannes 2009 Lions Festival.

PRAGUE, June 26 /PRNewswire/ --

- Milestone Release Gives a Glimpse of Things to Come in Intellij Idea 9, Makes Available Major New Features

JetBrains(R), creators of intelligent, productivity-enhancing tools for software developers, have announced the availability of IntelliJ(R) IDEA 9 Milestone Release 1, an official preview of the award-winning Java IDE due for release by the end of Fall 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070118/JBLOGO )

The Milestone release is an important step toward the next version of IntelliJ IDEA, designed to help developers stay in sync with the latest technologies, frameworks and languages.